Aqtual raises $16M for liquid biopsy test for rheumatoid arthritis based on cell-free DNA platform
Aqtual emerged from stealth on Tuesday with $16 million in Series A funds and plans to use its cell-free DNA platform to develop a blood test for patients with rheumatoid arthritis in the hopes of more quickly getting to the best treatment.
According to the California-based precision medicine company, there are more than 20 available drugs in six drug classes for rheumatoid arthritis — and most patients try two or three drugs before finding one that works best.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.